A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
NCT00267254
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- eligible for statin treatment for LDL cholesterol by NCEP guidelines
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects taking any drugs known to be associated with an increased risk of myositis in
combination with HMG-CoA reductase inhibitors.
- Subjects with significant liver or kidney disease or significant heart failure.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Mobile, Alabama
- Mesa, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Little Rock, Arkansas
- Los Angeles, California
- San Diego, California
- Santa Rosa, California
- Boynton Beach, Florida
- Melbourne, Florida
- Merritt Island, Florida
- Palm Bay, Florida
- Safety Harbor, Florida
- Tampa, Florida
- Chicago, Illinois
- Newton, Kansas
- Topeka, Kansas
- Wichita, Kansas
- Madisonville, Kentucky
- Boston, Massachusetts
- Ann Arbor, Michigan
- Canton, Michigan
- Portage, Michigan
- Troy, Michigan
- Minneapolis, Minnesota
- Kansas City, Missouri
- St. Louis, Missouri
- Butte, Montana
- Lincoln, Nebraska
- Las Vegas, Nevada
- Concord, New Hampshire
- Trenton, New Jersey
- Cooperstown, New York
- East Syracuse, New York
- Rochester, New York
- Charlotte, North Carolina
- Cincinnati, Ohio
- Clinton, South Carolina
- Cordova, Tennessee
- Memphis, Tennessee
- Milan, Tennessee
- Dallas, Texas
- Fort Worth, Texas
- San Antonio, Texas
- Payson, Utah
- Salt Lake City, Utah
- Norfolk, Virginia
- Milwaukee, Wisconsin
- Birmingham, Alabama
- Mesa, Arizona
- Alhambra, California
- Inglewood, California
- Los Angeles, California
- Santa Ana, California
- Wilmington, Delaware
- Fort Lauderdale, Florida
- Hollywood, Florida
- Jacksonville, Florida
- Merritt Island, Florida
- Pensacola, Florida
- Vero Beach, Florida
- Winter Park, Florida
- Atlanta, Georgia
- Conyers, Georgia
- Woodstock, Georgia
- Hinsdale, Illinois
- La Grange, Illinois
- Park Ridge, Illinois
- Springfield, Illinois
- Kansas City, Kansas
- Lexington, Kentucky
- Baltimore, Maryland
- Bethesda, Maryland
- Elkton, Maryland
- Flint, Michigan
- Springfield, Missouri
- Lawrenceville, New Jersey
- Albany, New York
- Seaford, New York
- Charlotte, North Carolina
- Cincinnati, Ohio
- Mansfield, Ohio
- Hillsboro, Oregon
- Beaver, Pennsylvania
- Flourtown, Pennsylvania
- Philadelphia, Pennsylvania
- Yardley, Pennsylvania
- Greenville, South Carolina
- Collierville, Tennessee
- Kingsport, Tennessee
- Knoxville, Tennessee
- North Richland Hills, Texas
- Spring, Texas
- Salt Lake City, Utah
- West Jordan, Utah
- Richmond, Virginia
- Bellevue, Washington
- Puyallup, Washington
- Tacoma, Washington
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol. | |||
Official Title ICMJE | A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) | |||
Brief Summary | The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another. | |||
Detailed Description | For additional information please call: 1-800-718-1021 | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 640 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | August 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00267254 | |||
Other Study ID Numbers ICMJE | A5091030 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |